The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

Leerink analyst warned that Moderna (NASDAQ:MRNA) shares could fall more than 30% if interim results from its Phase 3 CMV ...

Shares of Moderna Inc. MRNA slipped 9.07% to $41.51 Tuesday, on what proved to be an all-around grim trading session for the ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...

The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key ...